Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Dyschromia Therapeutics Market

<< Previous

Bullboard Posts

Next >>

Post by biorunon Mar 30, 2022 9:11pm

161 Views

Post# 34561247

Dyschromia Therapeutics Market

How many top10 global pharma's are listed below. I see at least two (Bayer and Abbvie).

https://www.biospace.com/article/dyschromia-therapeutics-market-increase-in-awareness-about-the-importance-of-personal-appearance-to-drive-the-market/

https://pharmaboardroom.com/articles/top-10-global-pharma-companies-2021/

Leading companies operating in the global dyschromia therapeutics market are: